Aaron Ondrey - Sep 8, 2023 Form 3 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role: Interim CFO
Signature: /s/ John Moriarty, Attorney-in-Fact
Stock symbol: MRTX
Transactions as of: Sep 8, 2023
Transactions value $: $0
Form type: 3
Date filed: 9/12/2023, 05:27 PM
Next filing: Jan 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MRTX	Common Stock						14K	Sep 8, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MRTX	Employee Stock Option (Right to Buy)							Sep 8, 2023	Common Stock	11.9K	$65.79	Direct	F2
holding	MRTX	Employee Stock Option (Right to Buy)							Sep 8, 2023	Common Stock	11.8K	$45.66	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents Restricted Stock Unit grants with vesting periods of 4 years that vest 25% annually from grant date, which were August 1, 2022 and January 20, 2023.
F2	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was August 1, 2022 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
F3	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was January 20, 2023 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.